Medcool Spółka z Ograniczoną Odpowiedzialnością (KRS 0000948383, NIP 9492252900) is a Polish company, headquartered in Zielona Góra, Lubuskie voivodeship. MEDCOOL operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since January 21, 2022. MEDCOOL's most recently reported net revenue was 0 PLN for 2024.
Negative equity
Negative equity in 1 of 2 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Medcool
Identity
- Name
- Medcool Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- January 21, 2022
- Registry status as of
- July 6, 2026
- Latest entry
- July 6, 2026
- Founding act
- 20.01.2022R.
Articles of association history (2)
- January 20, 2022: 20.01.2022R.
- September 9, 2022: 09.09.2022 R. NOTARIUSZ GRZEGORZ GILER, KANCELARIA NOTARIALNA IWONA BOGUSŁAWSKA, RENATA CHOROMAŃSKA, ROBERT GILER, WALDEMAR GŁADKOWSKI, MATEUSZ TEPEREK, GRZEGORZ GILER, ANNA KISIELEWSKA-DRUŻDŻ, ANNA KAŹMIERCZAK SP.P., REP. A NR 24950/2022; ZMIANA UMOWY SPÓŁKI POPRZEZ UCHYLENIE DOTYCHCZASOWEGO TEKSTU JEDNOLITEGO UMOWY SPÓŁKI I PRZYJĘCIE NOWEGO TEKSTU UMOWY SPÓŁKI STANOWIĄCEGO NOWY TEKST JEDNOLITY UMOWY SPÓŁKI; 16.11.2022 R. NOTARIUSZ MATEUSZ TEPEREK, KANCELARIA NOTARIALNA IWONA BOGUSŁAWSKA, RENATA CHOROMAŃSKA, ROBERT GILER, WALDEMAR GŁADKOWSKI, MATEUSZ TEPEREK, GRZEGORZ GILER, ANNA KISIELEWSKA-DRUŻDŻ, ANNA KAŹMIERCZAK SP.P., REP. A NR 31961/2022; ZMIANA § 1 I § 17.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. NOWY KISIELIN-A. SYRKIEWICZA, 6, 66-002, ZIELONA GÓRA, POLSKA
- Voivodeship
- LUBUSKIE
- District
- ZIELONA GÓRA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Medcool
Credibility rating
20.2 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
52
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/4 yrs
Board changes
1
1/4 yrs
PKD changes
0
0/4 yrs
Name changes
0
0/4 yrs
Data from 4 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: E (20/100)
Trend: deteriorating (-11.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2023–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Medcool
Founded
January 21, 2022
4 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ZIELONA GÓRA
LUBUSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
9.8 K PLN
196 shares total
Shareholders
3
shareholders
Board
2 people
Filed years
2 years
2023–2024 · profitable: 0/2
Registry entries
13
latest: July 6, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
-30.7 K PLN
2024
Assets
20.7 K PLN
2024
Equity
-20.9 K PLN
2024
Valuation
10.6 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Medcool.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
